injection of CNK-UT009
Phase 1Small molecule
injection of CNK-UT009 is one of 52 small molecule programs targeting Inflammatory Bowel Disease. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
61 competitors in Inflammatory Bowel Disease
#DrugCompanyPhaseTrials
1Remicade
Johnson & JohnsonApproved
Humira
NovartisApproved
Skyrizi
AbbVieApproved
Dificlir
Merck & Co.Approved
Mounjaro
Eli LillyApproved
Elavil
AstraZenecaApproved
Calciferol
Jazz PharmaceuticalsApproved
Zyloprim
Jazz PharmaceuticalsApproved
Vancocin
HHikma Pharmaceuticals LLC
Approved
Spravato
WWim Janssens
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Inflammatory Bowel Disease1 trial
Safety and Efficiency of the Universal CNK-UT009 in Difficult-to-treat Inflammatory Bowel Disease Patients
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT07416383·40 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for injection of CNK-UT009. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details